Literature DB >> 10760607

Treatment of separation anxiety in dogs with clomipramine: results from a prospective, randomized, double-blind, placebo-controlled, parallel-group, multicenter clinical trial.

.   

Abstract

The efficacy and tolerability of clomipramine in the treatment of separation anxiety in dogs was tested in a prospective, randomized, double-blind, placebo-controlled, parallel-group, international multicenter clinical trial. For a diagnosis of separation anxiety, dogs had to exhibit at least one of the following signs in the absence of their owner: destruction, defecation, urination and/or vocalization, as well as the behaviour suggestive of "hyper-attachment" to their owner. A total of 95 dogs were randomized to receive one of the three treatments for 2-3 months: "standard-dose" clomipramine (1 to <2 mg/kg, PO, q. 12 h); "low-dose" clomipramine (0.5 to <1 mg/kg, PO, q. 12 h); and placebo (PO, q. 12 h). All dogs received behavioural therapy. Dogs were examined at four time points (days 0, 28, 56 and 84) after the initiation of therapy. Improvement in each dog's behaviour at days 28, 56 and 84 was evaluated in comparison to its behaviour at day 0.The results showed that, compared to placebo, dogs receiving standard-dose clomipramine were rated improved at least three times faster for the signs destruction, defecation and urination. At most time points, more dogs in the standard-dose clomipramine group were rated improved for the signs destruction, defecation and urination, and in an owner's global assessment of the dog's overall behaviour (p<0.05 at certain time points). However, there were no statistically significant differences at any time point between the standard dose and the placebo groups in the sign vocalization. The low-dose clomipramine group produced no statistically significant effect when compared with placebo. Mild and transient vomiting was noted as a side effect of clomipramine in a small number of dogs.It is concluded that addition of standard-dose (1 to <2 mg/kg, PO, q. 12 h) clomipramine to conventional behavioural therapy for 2-3 months ameliorated the signs of separation anxiety in dogs.

Entities:  

Year:  2000        PMID: 10760607     DOI: 10.1016/s0168-1591(99)00127-6

Source DB:  PubMed          Journal:  Appl Anim Behav Sci        ISSN: 0168-1591            Impact factor:   2.448


  16 in total

Review 1.  Construct models in veterinary behavioural medicine: lessons from the human experience.

Authors:  G Sheppard; D S Mills
Journal:  Vet Res Commun       Date:  2003-04       Impact factor: 2.459

2.  Placebo-controlled double-blind clomipramine trial for the treatment of anxiety or fear in beagles during ground transport.

Authors:  Diane Frank; Audrey Gauthier; Renée Bergeron
Journal:  Can Vet J       Date:  2006-11       Impact factor: 1.008

3.  Redirecting Imipramine against Bluetongue Virus Infection: Insights from a Genome-wide Haploid Screening Study.

Authors:  Lijo John; Caroline Vernersson; Hyesoo Kwon; Ulrich Elling; Josef M Penninger; Ali Mirazimi
Journal:  Pathogens       Date:  2022-05-22

4.  Clinical trials involving cats: what factors affect owner participation?

Authors:  Margaret E Gruen; Katrina N Jiamachello; Andrea Thomson; B Duncan X Lascelles
Journal:  J Feline Med Surg       Date:  2014-06-17       Impact factor: 2.015

5.  Dogs with separation-related problems show a "less pessimistic" cognitive bias during treatment with fluoxetine (Reconcile™) and a behaviour modification plan.

Authors:  Christos I Karagiannis; Oliver Hp Burman; Daniel S Mills
Journal:  BMC Vet Res       Date:  2015-03-28       Impact factor: 2.741

6.  Influence of owners' attachment style and personality on their dogs' (Canis familiaris) separation-related disorder.

Authors:  Veronika Konok; András Kosztolányi; Wohlfarth Rainer; Bettina Mutschler; Ulrike Halsband; Ádám Miklósi
Journal:  PLoS One       Date:  2015-02-23       Impact factor: 3.240

7.  The Effect of Pet Remedy on the Behaviour of the Domestic Dog (Canis familiaris).

Authors:  Sienna Taylor; Joah Madden
Journal:  Animals (Basel)       Date:  2016-10-25       Impact factor: 2.752

8.  A New Metric for Quantifying the Relative Impact of Risk Factors on Loss of Working Life Illustrated in a Population of Working Dogs.

Authors:  Geoffrey Caron-Lormier; Naomi D Harvey; Gary C W England; Lucy Asher
Journal:  PLoS One       Date:  2016-11-09       Impact factor: 3.240

9.  The use of imepitoin (Pexion™) on fear and anxiety related problems in dogs - a case series.

Authors:  Kevin J McPeake; Daniel S Mills
Journal:  BMC Vet Res       Date:  2017-06-13       Impact factor: 2.741

10.  Comparative evaluation between hypericin (hypiran) and fluoxetine in treatment of companion dogs with tail chasing.

Authors:  Bahman Mosallanejad; Hossein Najafzadeh Varzi; Reza Avizeh; Mahdi Pourmahdi; Fatemeh Khalili
Journal:  Vet Res Forum       Date:  2015-06-15       Impact factor: 1.054

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.